Somewhere between 35 and 50, most men start quietly conceding ground.

The workout that used to leave you energised now leaves you flat for two days. The 10pm second wind that made you productive in your twenties has become an 8pm wall. Recovery takes longer. Motivation dips earlier. Your GP looks at your blood work, tells you everything is "within normal range," and sends you home with the implicit message that this is simply what happens.

It is not.

What you are experiencing is not the inevitable tax of a birthday. It is the cumulative effect of a biological operating system that has drifted out of calibration — and the individual subsystems are more modifiable than most men have been led to believe.

Here is what the research actually shows.

When men describe fatigue, they tend to frame it as a single problem. In the biology, it is almost always four problems talking over each other.

1. Mitochondrial capacity. Your mitochondria are the cellular machinery that converts food and oxygen into ATP — the energy currency your body runs on. The number of mitochondria per cell, their efficiency, and their ability to regenerate all decline with age. Research from the Salk Institute and others has shown that mitochondrial density in skeletal muscle can decline by 30 to 50 percent between age 30 and 70 in sedentary men. The same studies show that much of this loss is reversible with the right training stimulus. The fatigue you feel climbing stairs at 45 is not your age; it is your mitochondrial count.

2. Hormonal signalling. Testosterone is the hormone men talk about. The ones they should also be talking about are free testosterone, SHBG, DHEA-S, IGF-1, thyroid (TSH, free T3, free T4), and cortisol rhythm. These hormones operate as a system, not as individual numbers. A "normal" total testosterone with elevated SHBG, suppressed free T3, and a flat cortisol curve is a profile of exhaustion — and a standard GP panel will often report every marker as being in range.

3. Circadian architecture. Sleep is not a single variable. Your body runs on roughly 100 internal clocks, all of which are synchronised by light, temperature, movement, and feeding cues. The modern male environment — blue light past 10pm, inconsistent bedtimes, late eating, irregular caffeine — desynchronises these clocks. The result is not just poor sleep quality. It is suppressed morning testosterone, elevated evening cortisol, impaired glucose handling, and the particular kind of fatigue that does not improve with an extra hour in bed.

4. Metabolic flexibility. The ability to switch cleanly between burning carbohydrate and burning fat is one of the clearest markers of metabolic health. Men who have lost this flexibility — common by 40 in the developed world — experience energy as a series of crashes and cravings rather than a smooth continuous supply. Continuous glucose monitoring data published in Cell Metabolism last year showed that metabolically inflexible men had roughly twice the postprandial glucose excursions of flexible men on identical meals. You feel this as the 3pm slump.

The interventions that show the clearest evidence for restoring male energy are not exotic. They are boring, specific, and stacked.

Zone 2 training, three to four sessions a week. The single most well-supported intervention for rebuilding mitochondrial density. Zone 2 is the intensity at which you can still hold a conversation — typically 60 to 70 percent of max heart rate. It is deliberately unsexy. It also produces measurable increases in mitochondrial biogenesis, fat oxidation, and lactate clearance within 8 to 12 weeks. Add one VO2 max session per week for the ceiling.

Resistance training, twice a week minimum. Skeletal muscle is an endocrine organ. Men who resistance train in their 40s and 50s have consistently higher free testosterone, better insulin sensitivity, and better mood profiles than matched sedentary controls. The dose response is clear. Two full-body sessions of 45 minutes beats no sessions by a wide margin; four does not beat two by as much as you think.

Protein above 1.6 grams per kilogram of bodyweight. Most men over 40 are underfed protein. The research on sarcopenia prevention is unambiguous: higher protein intake, distributed across meals, preserves muscle mass and mitochondrial function. For an 85 kg man, that is roughly 140 grams a day — a number most men hit only with deliberate planning.

Light discipline. Morning light exposure within 30 minutes of waking, and minimisation of blue-spectrum light after sunset. This single habit, when held for 30 days, measurably shifts melatonin onset earlier and morning cortisol higher.

Sleep temperature and consistency. A cool bedroom (16 to 18 degrees Celsius), a consistent bedtime within a 30-minute window, and no food within three hours of sleep. These three levers account for more sleep architecture improvement than every supplement on the market combined.

Selective hormonal intervention. For men whose free testosterone is genuinely low and whose symptoms are consistent with hypogonadism, testosterone replacement therapy — properly prescribed and monitored — is the single highest-leverage intervention available. The cardiovascular safety question has now been answered (see Edition #1). For men whose numbers are borderline, the first-line interventions above usually move them out of the grey zone without pharmacology.

Targeted peptide protocols. For men with recovery-limited training adaptation or specific tissue repair needs, peptides like BPC-157, CJC-1295, and MOTS-c are showing genuine signal in both animal and early human data. Access is improving. The evidence base is thinner than the marketing suggests.

Male fatigue in the 30s, 40s, and 50s is not a single problem with a single fix. It is a four-system drift — mitochondrial, hormonal, circadian, metabolic — that responds to a specific set of inputs.

The inputs are not secret. They are not expensive. They are not even particularly new.

What has changed is that the tools for measuring them accurately — blood panels, continuous glucose monitors, wearable sleep tracking, DEXA scans, VO2 max testing — are now available to ordinary men without a research budget. For the first time, you can run your own calibration.

You are not aging out of energy. You are running on factory settings that no one bothered to update.

That is fixable.

Four stories worth your attention this week — one each from peptides, testosterone, regenerative medicine, and the tools worth tracking.

Peptides — The FDA has reopened access to 14 compounded peptides, including BPC-157 and CJC-1295. NPR's late-March report brings mainstream coverage to the HHS reclassification first announced in February. Licensed compounding pharmacies can once again prepare these peptides under physician prescription. Access is expanding. The clinical evidence base has not expanded with it. (NPR, 31 March 2026)

Testosterone — A 9,000-man real-world cohort confirms TRT safety outside the trial setting. Published in the World Journal of Men's Health, this longitudinal analysis moves the evidence beyond TRAVERSE's controlled environment and into everyday prescribing. The findings: favourable safety profile, measurable improvement in sexual function and quality-of-life metrics. This is the kind of data that turns guideline intent into clinical confidence. (World Journal of Men's Health, 2026)

Regenerative medicine — The first clinical signal that senolytics may improve cognition in ageing adults. A pilot trial in eBioMedicine tested a dasatinib-plus-quercetin protocol in older adults with mild cognitive impairment. Twelve weeks in, the group showed a two-point improvement on the Montreal Cognitive Assessment, reduced inflammatory markers, and no serious adverse events. Small trial. First clinical evidence that clearing senescent cells might actually translate into cognitive benefit. Worth watching closely. (eBioMedicine / The Lancet, January 2025)

Biohacking — Continuous glucose monitors have crossed from diabetes tool to mainstream metabolic device. STAT News reports on the FDA-cleared non-diabetic rollout of Dexcom Stelo and Abbott Lingo, and the clinical evidence behind it. For men without a diabetes diagnosis, CGM is emerging as the highest-resolution view you can get into how your own body handles food, training, and sleep — data that was research-grade a decade ago. (STAT News, 20 August 2025)

The most useful thing that has happened to male health in the last five years is not a drug, a peptide, or a device. It is the democratisation of measurement.

A man in 2026 can measure his free testosterone, SHBG, continuous glucose, VO2 max, sleep architecture, and body composition for less than the cost of a gym membership. Twenty years ago, most of that required a research lab. Today it requires a postal blood test and a wearable.

This changes the conversation. It moves the argument from "is this a real problem?" to "here are your numbers, here is where they should be, here is what moves them." The old model — your GP tells you what is normal based on population averages — is being quietly replaced by personal baselines and trend data.

The men who benefit most from this shift are not the ones chasing optimisation. They are the ordinary men who have been told for a decade that their fatigue, low mood, and stalled progress are simply what 45 looks like.

It is not.

That is Edition #2. If you read only one section this week, make it the four systems above. Most men have never had the problem described to them accurately.

Next week: the GLP-1 question no one is asking about long-term testosterone, and a closer look at the new VO2 max home-testing devices.

If this was worth your time, forward it to one man who has been told his fatigue is just his age.

The Longevity Brief — independent longevity intelligence for men who think for themselves.